Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer

Prostate

Volumn 73, Issue 6, 2013, Pages 657-667

  Nordin, Anna ^a   Wang, Wanzhong ^a   Welén, Karin ^a   Damber, Jan Erik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CHROMOGRANIN A; MIDKINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CASTRATION RESISTANT PROSTATE CANCER; CELL DIFFERENTIATION; CONTROLLED STUDY; EARLY CANCER; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NEUROSECRETORY CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION;

AGED; AGED, 80 AND OVER; ANDROGENS; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TUBULIN; UP-REGULATION;

EID: 84875794695     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22607     Document Type: Article

References (51)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46 (4): 765-781.
2. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics. CA Cancer J Clin 2010; 60 (5): 277-300.
3. Heinlein CA, Chang C,. Androgen receptor in prostate cancer. Endocr Rev 2004; 25 (2): 276-308.
4. Debes JD, Tindall DJ,. Mechanisms of androgen-refractory prostate cancer. N Engl J Med 2004; 351 (15): 1488-1490.
5. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39.
6. Isaacs JT, Isaacs WB,. Androgen receptor outwits prostate cancer drugs. Nat Med 2004; 10 (1): 26-27.
7. Yuan TC, Veeramani S, Lin MF,. Neuroendocrine-like prostate cancer cells: Neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr Relat Cancer 2007; 14 (3): 531-547.
8. Ismail AH, Landry F, Aprikian AG, Chevalier S,. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate 2002; 51 (2): 117-125.
9. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N,. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45 (5): 586-592; discussion 592.
10. Ito T, Yamamoto S, Ohno Y, Namiki K, Aizawa T, Akiyama A, Tachibana M,. Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence. Oncol Rep 2001; 8 (6): 1221-1224.
11. Abrahamsson PA,. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6 (4): 503-519.
12. Roudier MP, True LD, Vessella RL, Higano CS,. Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity. J Clin Pathol 2004; 57 (3): 321-323.
13. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S,. The pathologic classification of neuroendocrine tumors: A review of nomenclature, grading, and staging systems. Pancreas 2010; 39 (6): 707-712.
14. Sun Y, Niu J, Huang J,. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1 (2): 148-162.
15. Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP,. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009; 69 (1): 151-160.
16. Lee LF, Guan J, Qiu Y, Kung HJ,. Neuropeptide-induced androgen independence in prostate cancer cells: Roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001; 21 (24): 8385-8397.
17. Wright ME, Tsai MJ, Aebersold R,. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003; 17 (9): 1726-1737.
18. Frigo DE, McDonnell DP,. Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation. Mol Cancer Ther 2008; 7 (3): 659-669.
19. Kadomatsu K, Muramatsu T,. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004; 204 (2): 127-143.
20. Muramatsu T,. Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem 2002; 132 (3): 359-371.
21. Yao X, Tan Z, Gu B, Wu RR, Liu YK, Dai LC, Zhang M,. Promotion of self-renewal of embryonic stem cells by midkine. Acta Pharmacol Sin 2010; 31 (5): 629-637.
22. Takei Y, Kadomatsu K, Goto T, Muramatsu T,. Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts. Cancer 2006; 107 (4): 864-873.
23. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao Y, Muramatsu T, Kadomatsu K,. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999; 57 (3): 253-257.
24. You Z, Dong Y, Kong X, Beckett LA, Gandour-Edwards R, Melamed J,. Midkine is a NF-kappaB-inducible gene that supports prostate cancer cell survival. BMC Med Genomics 2008; 1: 6.
25. Ruan M, Ji T, Wu Z, Zhou J, Zhang C,. Evaluation of expression of midkine in oral squamous cell carcinoma and its correlation with tumour angiogenesis. Int J Oral Maxillofac Surg 2007; 36 (2): 159-164.
26. Mashour GA, Ratner N, Khan GA, Wang HL, Martuza RL, Kurtz A,. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001; 20 (1): 97-105.
27. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R,. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res 1997; 57 (9): 1814-1819.
28. Chen S, Bu G, Takei Y, Sakamoto K, Ikematsu S, Muramatsu T, Kadomatsu K,. Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells. J Cell Sci 2007; 120 (Pt 22): 4009-4015.
29. Kadomatsu K, Hagihara M, Akhter S, Fan QW, Muramatsu H, Muramatsu T,. Midkine induces the transformation of NIH3T3 cells. Br J Cancer 1997; 75 (3): 354-359.
30. Ratovitski EA, Kotzbauer PT, Milbrandt J, Lowenstein CJ, Burrow CR,. Midkine induces tumor cell proliferation and binds to a high affinity signaling receptor associated with JAK tyrosine kinases. J Biol Chem 1998; 273 (6): 3654-3660.
31. Xu Y, Qu X, Zhang X, Luo Y, Zhang Y, Hou K, Liu Y,. Midkine positively regulates the proliferation of human gastric cancer cells. Cancer Lett 2009; 279 (2): 137-144.
32. Ohuchida T, Okamoto K, Akahane K, Higure A, Todoroki H, Abe Y, Kikuchi M, Ikematsu S, Muramatsu T, Itoh H,. Midkine protects hepatocellular carcinoma cells against TRAIL-mediated apoptosis through down-regulation of caspase-3 activity. Cancer 2004; 100 (11): 2430-2436.
33. Sasaki T, Komiya A, Suzuki H, Shimbo M, Ueda T, Akakura K, Ichikawa T,. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Eur Urol 2005; 48 (2): 224-229; discussion 229-230.
34. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H,. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167 (2 Pt 1): 512-515.
35. Kamiya N, Akakura K, Suzuki H, Isshiki S, Komiya A, Ueda T, Ito H,. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003; 44 (3): 309-314; discussion 314.
36. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H,. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009; 16 (1): 37-44.
37. Abrahamsson PA, Falkmer S, Falt K, Grimelius L,. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker ". Pathol Res Pract 1989; 185 (3): 373-380.
38. Vashchenko N, Abrahamsson PA,. Neuroendocrine differentiation in prostate cancer: Implications for new treatment modalities. Eur Urol 2005; 47 (2): 147-155.
39. Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, Tarabuzzi R, Poggio M, Torta M, Fontana D, Angeli A,. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001; 12 (Suppl. 2): S153-S157.
40. Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF,. Serum chromogranin-A in advanced prostate cancer. BJU Int 2001; 88 (7): 790-796.
41. Katsetos CD, Herman MM, Mork SJ,. Class III beta-tubulin in human development and cancer. Cell Motil Cytoskeleton 2003; 55 (2): 77-96.
42. Terry S, Ploussard G, Allory Y, Nicolaiew N, Boissiere-Michot F, Maille P, Kheuang L, Coppolani E, Ali A, Bibeau F, Culine S, Buttyan R, de la Taille A, Vacherot F,. Increased expression of class III beta-tubulin in castration-resistant human prostate cancer. Br J Cancer 2009; 101 (6): 951-956.
43. Stengel C, Newman SP, Leese MP, Potter BV, Reed MJ, Purohit A,. Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 2010; 102 (2): 316-324.
44. Seve P, Dumontet C,. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol 2008; 9 (2): 168-175.
45. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA,. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997; 36 (12): 3554-3562.
46. Katsetos CD, Kontogeorgos G, Geddes JF, Herman MM, Tsimara-Papastamatiou H, Yu Y, Sakkas LI, Tsokos M, Patchefsky AS, Ehya H, Cooper HS, Provencio J, Spano AJ, Frankfurter A,. Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. Arch Pathol Lab Med 2000; 124 (4): 535-544.
47. Qi M, Ikematsu S, Maeda N, Ichihara-Tanaka K, Sakuma S, Noda M, Muramatsu T, Kadomatsu K,. Haptotactic migration induced by midkine. Involvement of protein-tyrosine phosphatase zeta. Mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. J Biol Chem 2001; 276 (19): 15868-15875.
48. Huang Y, Hoque MO, Wu F, Trink B, Sidransky D, Ratovitski EA,. Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle 2008; 7 (11): 1613-1622.
49. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA,. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000; 42 (4): 274-279.
50. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, Lucera R, Di Silverio F,. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003; 55 (3): 168-179.
51. Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L,. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy. Prostate 70 (7): 718-726.